(Adds comment on currency impact, outlook.)
BASEL, Switzerland (Dow Jones)--Swiss drug maker Roche Holding AG (ROG.VX) Wednesday reduced its peak sales estimate for cancer drug Avastin to around 7 billion Swiss francs ($7.4 billion), from a previous estimate of about CHF9 billion.
The reduction was partly due to a recent decision by the U.S. Food and Drug Administration
No comments:
Post a Comment